<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Meyer C</submitter><funding>Wilhelm Sander-Stiftung</funding><funding>Deutsche Forschungsgemeinschaft</funding><funding>Medical Research Council</funding><pagination>988-1005</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10169636</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>37(5)</volume><pubmed_abstract>Chromosomal rearrangements of the human KMT2A/MLL gene are associated with de novo as well as therapy-induced infant, pediatric, and adult acute leukemias. Here, we present the data obtained from 3401 acute leukemia patients that have been analyzed between 2003 and 2022. Genomic breakpoints within the KMT2A gene and the involved translocation partner genes (TPGs) and KMT2A-partial tandem duplications (PTDs) were determined. Including the published data from the literature, a total of 107 in-frame KMT2A gene fusions have been identified so far. Further 16 rearrangements were out-of-frame fusions, 18 patients had no partner gene fused to 5'-KMT2A, two patients had a 5'-KMT2A deletion, and one ETV6::RUNX1 patient had an KMT2A insertion at the breakpoint. The seven most frequent TPGs and PTDs </pubmed_abstract><journal>Leukemia</journal><pubmed_title>The KMT2A recombinome of acute leukemias in 2023.</pubmed_title><pmcid>PMC10169636</pmcid><funding_grant_id>MA 1876/12-1</funding_grant_id><funding_grant_id>2018.070.2</funding_grant_id><funding_grant_id>MR/S021590/1</funding_grant_id><pubmed_authors>Delabesse E</pubmed_authors><pubmed_authors>Lentes J</pubmed_authors><pubmed_authors>Montonen M</pubmed_authors><pubmed_authors>Kubetzko S</pubmed_authors><pubmed_authors>Ballerini P</pubmed_authors><pubmed_authors>Groger D</pubmed_authors><pubmed_authors>Hancock J</pubmed_authors><pubmed_authors>Fechina L</pubmed_authors><pubmed_authors>Arfeuille C</pubmed_authors><pubmed_authors>Sutton R</pubmed_authors><pubmed_authors>Bomken S</pubmed_authors><pubmed_authors>Moricke A</pubmed_authors><pubmed_authors>Kohrer S</pubmed_authors><pubmed_authors>Archer P</pubmed_authors><pubmed_authors>Menendez P</pubmed_authors><pubmed_authors>Meyer C</pubmed_authors><pubmed_authors>Silva MLM</pubmed_authors><pubmed_authors>Zur Stadt U</pubmed_authors><pubmed_authors>Burmeister T</pubmed_authors><pubmed_authors>Trautmann H</pubmed_authors><pubmed_authors>Sedek L</pubmed_authors><pubmed_authors>Corral Abascal L</pubmed_authors><pubmed_authors>Madsen HO</pubmed_authors><pubmed_authors>Emerenciano M</pubmed_authors><pubmed_authors>Lapillonne H</pubmed_authors><pubmed_authors>Sonneveld E</pubmed_authors><pubmed_authors>Bueno C</pubmed_authors><pubmed_authors>Izraeli S</pubmed_authors><pubmed_authors>Lundan T</pubmed_authors><pubmed_authors>Strehl S</pubmed_authors><pubmed_authors>Clappier E</pubmed_authors><pubmed_authors>Stanulla M</pubmed_authors><pubmed_authors>Zuna J</pubmed_authors><pubmed_authors>Dworzak MN</pubmed_authors><pubmed_authors>Van der Velden VHJ</pubmed_authors><pubmed_authors>Mason J</pubmed_authors><pubmed_authors>Grardel N</pubmed_authors><pubmed_authors>Kim J</pubmed_authors><pubmed_authors>Lo Nigro L</pubmed_authors><pubmed_authors>Alten J</pubmed_authors><pubmed_authors>Bergmann AK</pubmed_authors><pubmed_authors>Juvonen V</pubmed_authors><pubmed_authors>Trka J</pubmed_authors><pubmed_authors>Marschalek R</pubmed_authors><pubmed_authors>Larghero P</pubmed_authors><pubmed_authors>Almeida Lopes B</pubmed_authors><pubmed_authors>Bidet A</pubmed_authors><pubmed_authors>Haas OA</pubmed_authors><pubmed_authors>Venn NC</pubmed_authors><pubmed_authors>Shichrur K</pubmed_authors><pubmed_authors>Bruggemann M</pubmed_authors><pubmed_authors>Cazzaniga G</pubmed_authors><pubmed_authors>Lund-Aho T</pubmed_authors><pubmed_authors>Marcu V</pubmed_authors><pubmed_authors>Nebral K</pubmed_authors><pubmed_authors>Katsibardi K</pubmed_authors><pubmed_authors>Caye-Eude A</pubmed_authors><pubmed_authors>Schafer BW</pubmed_authors><pubmed_authors>Eckert C</pubmed_authors><pubmed_authors>Price R</pubmed_authors><pubmed_authors>Gameiro P</pubmed_authors><pubmed_authors>Tsaur G</pubmed_authors><pubmed_authors>Kim R</pubmed_authors><pubmed_authors>Keernik M</pubmed_authors><pubmed_authors>Cave H</pubmed_authors><pubmed_authors>Pombo-de-Oliveira MS</pubmed_authors><pubmed_authors>de Matos RRC</pubmed_authors><pubmed_authors>Szczepanski T</pubmed_authors></additional><is_claimable>false</is_claimable><name>The KMT2A recombinome of acute leukemias in 2023.</name><description>Chromosomal rearrangements of the human KMT2A/MLL gene are associated with de novo as well as therapy-induced infant, pediatric, and adult acute leukemias. Here, we present the data obtained from 3401 acute leukemia patients that have been analyzed between 2003 and 2022. Genomic breakpoints within the KMT2A gene and the involved translocation partner genes (TPGs) and KMT2A-partial tandem duplications (PTDs) were determined. Including the published data from the literature, a total of 107 in-frame KMT2A gene fusions have been identified so far. Further 16 rearrangements were out-of-frame fusions, 18 patients had no partner gene fused to 5'-KMT2A, two patients had a 5'-KMT2A deletion, and one ETV6::RUNX1 patient had an KMT2A insertion at the breakpoint. The seven most frequent TPGs and PTDs </description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 May</publication><modification>2026-07-14T21:16:35.822Z</modification><creation>2025-04-06T10:13:19.767Z</creation></dates><accession>S-EPMC10169636</accession><cross_references><pubmed>37019990</pubmed><doi>10.1038/s41375-023-01877-1</doi></cross_references></HashMap>